Related Experiment Video

Updated: Mar 27, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

High prevalence of raised lipoprotein(a) in patients with refractory angina

Tina Z Khan1, Samantha Rhodes1, Alison Pottle1

  • 1Harefield Hospital, London, United Kingdom.

Global Cardiology Science & Practice
|January 19, 2016
PubMed

Insights

A high prevalence of elevated lipoprotein(a) [Lp(a)] was found in patients with refractory angina. This suggests Lp(a) may play a role in this condition, warranting further investigation into potential treatments.

Area of Science:

  • Cardiology
  • Lipidology
  • Atherosclerosis Research

Background:

  • Refractory angina, difficult to treat with standard therapies, significantly impacts patients.
  • Elevated lipoprotein(a) [Lp(a)] is a recognized cardiovascular risk factor.
  • The prevalence of high Lp(a) in refractory angina patients was previously undefined.

Purpose of the Study:

  • To determine the prevalence of elevated lipoprotein(a) [Lp(a)] levels (>500 mg/L) in patients suffering from refractory angina.

Main Methods:

  • A pilot epidemiological screening study involved 75 refractory angina patients from a UK tertiary cardiac center.
  • Lipoprotein(a) [Lp(a)] levels were measured using an isoform-insensitive assay.
  • Fasting lipid profiles and conventional cardiovascular risk factors were also assessed.

Main Results:

  • 60% of the 75 refractory angina patients exhibited elevated Lp(a) levels (>500 mg/L).
  • The median Lp(a) level was 771 mg/L, with an interquartile range of 162-1260 mg/L.

Conclusions:

  • The high prevalence of elevated Lp(a) in this cohort suggests a potential causal role in refractory angina.
  • Further research, including prospective studies, is needed to confirm this association and explore Lp(a) reduction therapies.
Abstract

Keywords:
Coronary artery diseaseLipoprotein (a)Refractory anginaRisk factors

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

536
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
415
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
570
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
365
Angina I: Introduction01:30

Angina I: Introduction

Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
679